National Institute for Health and Care Excellence16h
In development: Guidance, quality standards and advice
12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280] Technology appraisal guidance 12 February 2025 Abaloparatide for treating ...
National Institute for Health and Care Excellence3d
Health inequalities modular update to NICE health technology evaluations: the manual (PMG36)
If you’re commenting for an organisation, your organisation needs to be registered as a stakeholder. We can accept comments from individuals. These will be considered, but you won’t get a formal ...
National Institute for Health and Care Excellence4d
Tirzepatide for managing overweight and obesity
Tirzepatide is recommended as an option for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity in adults, only if they have: an initial body mass index ...
National Institute for Health and Care Excellence4d
Tirzepatide for managing overweight and obesity
The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...
National Institute for Health and Care Excellence4d
Tirzepatide for managing overweight and obesity
Tirzepatide (Mounjaro, Eli Lilly) is a long-acting dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide‑1 (GLP‑1) receptor agonist for subcutaneous injection with a ...
National Institute for Health and Care Excellence4d
Health inequalities modular update to NICE health technology evaluations: the manual (PMG36)
A list of downloadable documents created during development.
National Institute for Health and Care Excellence4d
Tirzepatide for managing overweight and obesity
Tirzepatide (Mounjaro, Eli Lilly) is indicated for 'weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults ...
National Institute for Health and Care Excellence4d
Tirzepatide for managing overweight and obesity
Tirzepatide's gastrointestinal adverse effects could lead to dehydration and in turn a deterioration in renal function including acute renal failure. Older people and some other groups of people may ...
National Institute for Health and Care Excellence4d
Tirzepatide for managing overweight and obesity
NICE's medicines practice guideline on developing and updating local formularies recommends that medicines recommended in NICE technology appraisals are adopted into local formularies automatically ...
National Institute for Health and Care Excellence4d
Tirzepatide for managing overweight and obesity
In SURMOUNT‑1 and SURMOUNT‑2, 2,519 people had tirzepatide alone or in combination with other glucose-lowering medicines. The most frequently reported adverse reactions were gastrointestinal disorders ...
National Institute for Health and Care Excellence4d
Tirzepatide for managing overweight and obesity
NICE has produced a resource impact assessment tool for tirzepatide. NICE estimates that the total eligible population is 3.4 million people, and expects that an interim NHS England commissioning ...